Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies

Stuendl et al. show that CSF exosomes of patients with Parkinson’s disease or dementia with Lewy bodies contain α-synuclein and induce α-synuclein aggregation in a reporter cell line. Thus, exosomes may support inter-neuronal transmission of α-synuclein pathology. CSF exosomal α-synuclein may serve as a biomarker in α-synuclein-related neurodegeneration.

[1]  Tomohiro Kato,et al.  Serum peptides as candidate biomarkers for dementia with Lewy bodies , 2015, International journal of geriatric psychiatry.

[2]  K. Nie,et al.  Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis , 2015, The International journal of neuroscience.

[3]  S. Kügler,et al.  Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation , 2015, Acta Neuropathologica.

[4]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[5]  T. J. Cook,et al.  Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease , 2014, Acta Neuropathologica.

[6]  I. Sargent,et al.  Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  K. Blennow,et al.  Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[8]  He-Jin Lee,et al.  Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases , 2014, Nature Reviews Neurology.

[9]  J. Dear,et al.  Quantification of human urinary exosomes by nanoparticle tracking analysis , 2013, The Journal of physiology.

[10]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[11]  T. Friede,et al.  Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort , 2013, Neurology.

[12]  Aiman S Saab,et al.  Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–Neuron Communication , 2013, PLoS biology.

[13]  M. Helwig,et al.  Caudo-rostral brain spreading of α-synuclein through vagal connections , 2013, EMBO molecular medicine.

[14]  Ling-Zhi Wang,et al.  Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer , 2013, EMBO molecular medicine.

[15]  M. Wood,et al.  Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.

[16]  B. Mollenhauer,et al.  Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects , 2013, Neuroscience Letters.

[17]  D. Holtzman,et al.  Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. , 2012, Current opinion in neurology.

[18]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[19]  E. Morignat,et al.  Prion-like acceleration of a synucleinopathy in a transgenic mouse model , 2012, Neurobiology of Aging.

[20]  A. Winslow,et al.  Exosomal cell-to-cell transmission of alpha synuclein oligomers , 2012, Molecular Neurodegeneration.

[21]  A. Schneider,et al.  Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders , 2012, Cell and Tissue Research.

[22]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[23]  B. Mollenhauer,et al.  Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. , 2012, Methods.

[24]  Andrew F. Hill,et al.  Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases? , 2012, Front. Physio..

[25]  C. Frühbeis,et al.  Emerging Roles of Exosomes in Neuron–Glia Communication , 2012, Front. Physio..

[26]  R. Nussbaum,et al.  Basic Neurosciences, Genetics and Immunology -original Article A-synuclein in Human Cerebrospinal Fluid Is Principally Derived from Neurons of the Central Nervous System , 2022 .

[27]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[28]  Bernd Giebel,et al.  Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. , 2011, Colloids and surfaces. B, Biointerfaces.

[29]  Dongmei Sun,et al.  Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  M. Verbeek,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2011, Neurology.

[31]  Evangelia Emmanouilidou,et al.  Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma , 2011, PloS one.

[32]  Chris Gardiner,et al.  Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission , 2011, Neurobiology of Disease.

[33]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[34]  G. Krishnamoorthy,et al.  Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis , 2011, Journal of Cell Science.

[35]  B. Hyman,et al.  Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Jankovic,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[37]  T. Iwatsubo,et al.  Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. , 2010, The Journal of biological chemistry.

[38]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[39]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[40]  W. Möbius,et al.  Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in Niemann-Pick Type C Disease* , 2010, The Journal of Biological Chemistry.

[41]  A. Björklund,et al.  Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[42]  B. Mollenhauer,et al.  CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[43]  M. Ntzouni,et al.  Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival , 2010, The Journal of Neuroscience.

[44]  Jianqing Ding,et al.  Microglia in the aging brain: relevance to neurodegeneration , 2010, Molecular Neurodegeneration.

[45]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[46]  J. Kordower,et al.  Propagation of host disease to grafted neurons: Accumulating evidence , 2009, Experimental Neurology.

[47]  Michael Wolff,et al.  Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology , 2009, Journal of neurochemistry.

[48]  N. Bogdanovic,et al.  Blood-brain barrier alterations in ageing and dementia , 2009, Journal of the Neurological Sciences.

[49]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[50]  K. Blennow,et al.  Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.

[51]  T. Tokuda,et al.  CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease , 2009, Brain Research.

[52]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[53]  Bradley T. Hyman,et al.  Formation of Toxic Oligomeric α-Synuclein Species in Living Cells , 2008, PloS one.

[54]  S. Gould,et al.  Higher-Order Oligomerization Targets Plasma Membrane Proteins and HIV Gag to Exosomes , 2007, PLoS biology.

[55]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[56]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[57]  G. Lachenal,et al.  Exosomes are released by cultured cortical neurones , 2006, Molecular and Cellular Neuroscience.

[58]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  H. Braak,et al.  Staging of Sporadic Parkinson Disease-Related α-Synuclein Pathology: Inter- and Intra-Rater Reliability , 2005, Journal of neuropathology and experimental neurology.

[60]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[61]  J. Wiltfang,et al.  Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies , 2005, Dementia and Geriatric Cognitive Disorders.

[62]  Igor Stagljar,et al.  Application of the split-ubiquitin membrane yeast two-hybrid system to investigate membrane protein interactions. , 2004, Methods.

[63]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[65]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[66]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[67]  M. Vidal,et al.  Aggregation reroutes molecules from a recycling to a vesicle-mediated secretion pathway during reticulocyte maturation. , 1997, Journal of cell science.

[68]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[69]  Samir Guglani.  Death , 1890, The Lancet.

[70]  E. Masliah,et al.  Cell-to-cell transmission of α-synuclein aggregates. , 2012, Methods in molecular biology.

[71]  W. M. van der Flier,et al.  CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[72]  J. Kordower,et al.  Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another? , 2009, Neuropsychopharmacology.

[73]  T. Tokuda,et al.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[74]  J. Wiltfang,et al.  Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. , 2005, Dementia and geriatric cognitive disorders.

[75]  Kathryn E Luker,et al.  Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. , 2004, Methods in enzymology.

[76]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.